Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
309.8 USD | +1.28% | +2.21% | +6.53% |
May. 28 | US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment | RE |
May. 28 | Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.53% | 164B | |
+41.87% | 739B | |
+32.73% | 598B | |
-5.79% | 353B | |
+16.90% | 318B | |
+3.39% | 285B | |
+16.35% | 240B | |
+9.83% | 210B | |
-5.40% | 206B | |
+0.38% | 162B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Xeris Biopharma Shares Rise on Licensing Agreement With Amgen